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Abstract
Background: COVID-19 is a public health emergency with a high mortality rate and it reduces the patient’s Health-
Related Quality of Life (HRQoL) significantly. This effect is measured in the current study.
Methods: In a cross-sectional study in Iran, 320 randomly selected treated patients from COVID-19 were studied. To
collect the required data, we applied a questionnaire that included socio-demographic factors, clinical
characteristics, and questions on the patients’ HRQoL. Time trade-off (TTO) approach was used to measure the lost
HRQoL attributed to COVID-19. Besides, we applied a two-limit Tobit regression model to determine the effects of
the socio-demographic factors on patients’ health utility and the visual analogue scale approach was used to
estimate the perceived total current health status.
Results: The overall mean (SE) and median (IQR) of the health utility values were 0.863 (0.01) and 0.909 (0.21)
respectively. These values for the traders (those who were willing to lose a part of their remaining time of life to avoid
the disease) were estimated at 0.793 (0.01) and 0.848 (0.17), respectively. The lowest amount of utility value belonged
to the elderly (mean (SE) = 0.742 (0.04); median (IQR) = 0.765 (0.42)) and those living in rural areas (mean (SE)) = 0.804
(0.03); median (IQR) = 0.877 (0.30)). The univariate analysis showed that age, place of residence, and household size had
a statistically significant effect on health utility. Moreover, findings of the regression analysis indicated that the
participants’ age and hospitalization status were the key determinants of COVID-19 health utility value.
Conclusion: COVID-19 is associated with a substantial and measurable decrease in HRQoL. This decline in HRQoL can
be directly compared with that induced by systemic health states.
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Background
Novel coronavirus disease 2019 (COVID-19) caused by
severe acute respiratory syndrome virus coronavirus 2
(SARS-CoV-2) was first identified in the world in
Wuhan, China in December 2019. About 3 months later,
the outbreak of the virus was declared by the World
Health Organization (WHO) as a global health crisis and
a pandemic [1, 2]. COVID-19 is an acute respiratory
syndrome with common symptoms including fever,
cough, shortness of breath, muscle aches, tiredness, sore
throat, headache, and loss of smell and taste. Although,
this disease is mild in most people and can be treated
with no special treatment, in some people it can lead to
serious illness and even death [3, 4]. The mortality rate
and severity of the disease vary with age, underlying
medical conditions such as cardiovascular disease,
diabetes, cancer, and chronic respiratory disease and
other health conditions [5–7]. Evidence suggests that
COVID-19 has a negative effect on physical and mental
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health and health-related quality of life of COVID-19
patients [8–10].
Severe acute respiratory infections lead to illness,
death, and hospitalization of millions of people world-
wide annually, and are one of the main reasons for the
referral and hospitalization of the elderly and children
[11]. By July 8, 2020, SARS CoV had infected approxi-
mately 12 million people worldwide and killed over 540,
000 [12]. The rapid spread of COVID-19 worldwide has
placed a heavy burden on health systems and many
countries are facing a shortage of hospital equipment
and facilities, such as intensive care beds and ventilators.
In addition, the number of hospitalized patients with
COVID-19 has exceeded the standard capacity of hospi-
tals [13–15]. Despite the urgent need for appropriate
evidence for key decision-making, information about
COVID-19 in the world is still limited. Appropriate
epidemiological information is needed for proper policy-
making and to control COVID-19 [16]. One of this in-
formation is the utility value of the disease. Without
knowing the utility value of the disease, it is not possible
to calculate the burden of the disease and conduct eco-
nomic evaluation studies of preventive and therapeutic
interventions [17]. Utility value for a disease indirectly
indicates a patient’s Health-Related Quality of Life
(HRQoL) level [18, 19]. Depending on the severity of the
disease, age, and the underlying medical conditions,
COVID-19 imposes various physical and mental limita-
tions on patients [4, 10, 20].
The aim of the current study was to calculate the
disease utility for different degrees of Covid-19 in differ-
ent socio-economic subgroups. The findings of the study
can be used in economic evaluation studies and also in
calculating the burden of Covid-19 at different geo-
graphic levels.
Methods
Study design and participants
This cross-sectional, multicenter study was conducted
on treated patients from COVID-19 at three hospitals in
provinces of Kurdistan, West Azerbaijan, and Hamadan
in western and northwestern Iran between May 21,
2020, and June 18, 2020. The study population included
320 randomly selected individuals who were discharged
from hospitals over the past 2 weeks. To avoid overesti-
mating the disutility value for COVID-19 and to be able
to extract people’s logical and real judgments about the
effects of the disease on the HRQoL, we studied the
newly recovered patients. To calculate the minimum re-
quired sample size, we applied the Walters [21] formula
for non-normally distributed continuous data. In this
calculation, we considered a two-tailed 5% significance
level, 80% power, effect size (PNoether) of 0.57 (consistent
with those used in common association analyses), and
response rate of 80% which gives the estimated number






Diagnosis of COVID-19 was done by trained laboratory
staff using real-time reverse transcriptase polymerase-
chain-reaction (RT PCR) assay for nasal pharyngeal swab
specimens based on World Health Organization interim
guidance [22]. We included the laboratory-confirmed
cases in the analysis and only patients who did not wish to
participate in the study were excluded. For patients under
the age of 18 and those who were unable to speak, the
interview was conducted with the most literate member of
his/her family as a proxy, who was over 15 years old.
Data collection
To collect the required data, we applied a validated
Persian language questionnaire [17, 23] that included
sociodemographic factors as well as questions on the
patients’ HRQoL and clinical characteristics. The first
two sections were completed through a telephone
interview with the patients and the third section was
completed by studying the patient’s medical records.
The telephone interviews were conducted by three
trained nurses who were working at the hospital wards
dedicated to patients with COVID-19 under supervision
of the principal investigator. Sociodemographic variables
included age, gender, place of residence (urban/ rural),
education (illiterate/ non-university (elementary, middle,
and high school)/ university), having a job (yes/ no),
marital status (single/ married) during the disease,
household size, standardized monthly household ex-
penditure (monthly household expenditure is divided by
square root of household size), and having basic health
insurance (yes/ no). This part of the questionnaire was
completed self-reportedly.
Clinical characteristics cover information on having an
underlying disease (yes/ no), the patient’s hospitalization
condition during the disease (quarantine at home/ hos-
pitalized at general wards/ hospitalized at Intensive Care
Unit (ICU) without intubation/ and hospitalized at ICU
with intubation), hospitalization days, arterial blood
hemoglobin oxygen saturation (SpO2), and level of lung
involvement (non or minor/ poor/ moderate/ severe).
SpO2 was measured by pulse oximeter and reported as a
percentage in which normal reading is considered above
95%. The overall extent of pulmonary involvement was
determined objectively by the radiologists based on chest
computed tomography severity score (CT-SS). The ques-
tion on having an underlying disease was asked from the
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participants, but other clinical information was extracted
from the patients’ hospital records.
Measurement of utility value
The third part of the questionnaire included Time
Trade-off (TTO) questions to measure the COVID-19
utility value that we used before in a similar study [23].
We first asked the participants to imagine themselves in
an unrecovered condition of COVID-19. Then, the re-
spondent was asked how many months (X) of remaining
life they would give up to avoid the effects and compli-
cations of COVID-19 and live the rest of life in perfect
health. In all cases, in the first question, the amount of
X was considered as 72 months (6 years). This initial
time was selected large enough to avoid framing effect.
When the respondent agrees/ disagrees with this base-
line point, interviewer increases/ decreases the X num-
ber to such an extent that the respondent subjectively
becomes indifferent between their current health states
in the remaining life-years (Y) and perfect health state in
a shorter time and the participant considers equal value
for both conditions. Dividing x by y (x/y) defines the
COVID-19 disutility, and result of the expression of 1- (x/
y) presents its utility for each respondent. To measure the
Y amount, we applied the Iranian life table 2016, which
defines the gender-age standardized life expectancy [24].
The possible range for the TTO value is between zero for
those who are unwilling to lose any time of their life (non-
traders) and one for individuals who are willing to lose all
their remaining time of life to avoid the disease.
Besides, we used the visual analogue scale (VAS)
approach to measure the perceived total current health
status. The respondents were asked to rate their HRQoL
on a ruler, which was numbered between zero (worst
HRQoL) and 10 (best HRQoL).
Statistical analysis
The descriptive results of the study were presented using
statistics of number (with percentage), mean (with
standard error), and mean (with interquartile range
[IQR]) for all sociodemographic and clinical subgroups.
Because the utility variable has right-skewed distribution,
which is confirmed by Shapiro-Wilk test, we applied
non-parametric tests of Mann-Whitney and Kruskal
Wallis respectively to statistically compare the observed
differences of utility values for two and more than two
groups. The significance level was considered at a p-value
below 0.05. The expenses were changed from Iran’s
national currency to USD using the average exchange rate
(USD 1.00 = IRR 160000).
The Two-limit Tobit regression model was applied to
determine the effects of sociodemographic and clinical
factors on the amount of COVID-19 utility value. Upper
and lower limits were set at 1.00 and 0.00 respectively,
which corresponds to utility value ranges. In this ana-
lysis, we solved the non-normal distribution of the
dependent variable, utility value, by taking the logarithm
transform. Those variables that had a statistically signifi-
cant relationship with the level of disease utility in
univariate analysis were selected as dependent factors.
All statistical analyzes were performed using STATA
version 15 (Stata Crop LP, College Station, TX, USA).
Results
Out of 320 invited treated patients from COVID-19, 287
individuals accepted participation in the study (response
rate: 89.69%). Of these, 144 (50.17%) were women, 178
(62.02%) were over 40 years old, and 264 (92.31%) had
health insurance. About one-third (96 people) of the re-
spondents were non-traders.
Table 1 presents the descriptive statistics for COVID-
19 health utility value by different sociodemographic
subgroups. The overall mean (SE) and median (IQR) of
the health utility values were 0.863 (0.01) and 0.909
(0.21) respectively. These values for traders were esti-
mated at 0.793 (0.01) and 0.848 (0.17) respectively. The
lowest amount of utility value belonged to the elderly
(mean (SE) = 0.742 (0.04); median (IQR) = 0.765 (0.42))
and those living in rural areas (mean (SE)) = 0.804 (0.03);
median (IQR) = 0.877 (0.30)). Univariate analysis showed
that age, place of residence, and household size had a
statistically significant effect on disease utility.
Table 2 depicts the findings of estimated utility values
of COVID-19 for recovered patients with different
clinical characteristics. Out of 287 respondents, 107
(37.28%) had at least one underlying disease, 17 (5.92%)
were hospitalized at ICU, 95 (33.10%) were hospitalized
for more than 4 days, 217 (65.61%) had SpO2 below
normal values, and 33 (11.5%) had moderate and severe
pulmonary involvement. Factors of having an underlying
disease and disease severity (in terms of hospitalization
status and level of lung involvement) had a statistically
significant positive effect on obtained utility values. The
lowest utility values were recorded for intubated patients
(mean (SE) = 0.629 (0.13); median (IQR) = 0.727 (0.33)),
for those with severe lung involvement (mean (SE) =
0.651 (0.11); median (IQR) =0.684 (0.24)), and for partic-
ipants that had underlying diseases (mean (SE) = 0.818
(0.02); median (IQR) = 0.886 (0.26)) respectively. The re-
sults also showed that there was no statistically signifi-
cant difference in currently perceived health status of
the studied participants.
Table 3 presents the results of the two-limit Tobit
regression analysis. The findings indicated that the
participants’ age and hospitalization status were the key
determinants of COVID-19 utility value. Therefore, we
observed a statistically significant and negative association
between age and disease severity with the disease utility.
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Discussion
This multicenter study was performed to estimate the
health utility value and its clinical and socio-demographic
determinants among newly recovered patients from
COVID-19. The overall mean (median) of the disease was
obtained as 0.863 (0.909). This means that patients who
suffered from COVID-19 lost an average of 13.7% of their
HRQoL. However, if we exclude non-traders from the
analysis, the mean (median) of the disease utility will de-
crease significantly by 0.793 (0.848). In other words,
people who are severely affected by the disease lose an
average of 20.7% of their HRQoL. The findings indicated
that 33.35% of the respondents did not accept any time
trade-off to get perfect health; meaning that they consid-
ered the disease’s effects very insignificant and thought
that there was no threat to their health. Further analysis of
data confirmed this claim, as 57.29% of non-traders were
quarantined at home, compared to 35.60% of traders.
Besides, the overall mean of hospitalized days for non-
traders and traders was 3.16 and 3.88 respectively.
As expected, there was a significant negative associ-
ation between the severity of COVID-19 and the disease
utility. As the highest mean utility values were observed
for those patients who home-quarantined themselves






Mean (SE) Median (IQR)
Total 287 (100) 0.863 (0.01) 0.909 (0.21)
Traders 191 (66.55) 0.793 (0.01) 0.848 (0.17) < 0.01
Non-traders 96 (33.55) 1.00 (0.00) 1.00 (0.00)
Age groups
Young (< 40 yrs) 109 (37.98) 0.917 (0.01) 0.932 (0.11) < 0.01
Middle age (40–65 yrs) 115 (40.07) 0.877 (0.01) 0.886 (0.20)
Elderly (> 65 yrs) 63 (21.95) 0.742 (0.04) 0.765 (0.42)
Gender
Male 143 (49.83) 0.851 (0.02) 0.907 (0.23) 0.28
Female 144 (50.17) 0.874 (0.01) 0.909 (0.17)
Marital Status
Single 67 (23.51) 0.889 (0.02) 0.923 (0.08) 0.15
Married 218 (76.49) 0.853 (0.01) 0.899 (0.23)
Place of residence
Urban 250 (87.11) 0.871 (0.01) 0.920 (0.19) 0.03
Rural 37 (12.89) 0.804 (0.03) 0.877 (0.30)
Education
Illiterate 70 (25.36) 0.821 (0.02) 0.920 (0.31) 0.06
Non-university 136 (49.28) 0.862 (0.02) 0.899 (0.19)
University 70 (25.36) 0.893 (0.01) 0.908 (0.15)
Employed
Yes 125 (44.48) 0.882 (0.01) 0.904 (0.18) 0.09
No 156 (55.52) 0.846 (0.02) 0.928 (0.24)
Having basic insurance
Yes 264 (92.31) 0.863 (0.01) 0.909 (0.21) 0.76
No 22 (7.69) 0.851 (0.04) 0.889 (0.18)
Household dimension
< 3 persons 119 (41.46) 0.834 (0.02) 0.889 (0.24) 0.02
> 3 persons 168 (48.54) 0.882 (0.01) 0.924 (0.62)
Standardized household’s monthly cost
Lowest (< 50 USD) 193 (67.25) 0.870 (0.01) 0.909 (0.19) 0.29
Highest (> 50 USD) 94 (32.75) 0.846 (0.02) 0.906 (0.23)
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(0.896) and had minor lung infection (0.927), and the
lowest mean utility values belonged to the participants
who were intubated (0.629) and had severe lung involve-
ment (0.651). In other words, patients who were intu-
bated or had severe lung involvement lost 37.1 and
34.9% of their HRQoL respectively. However, we did not
observe such statistically significant associations for
SpO2 levels and the number of hospital days. These
results suggest that variables of the patient’s
hospitalization and lung health status are appropriate in-
dicators for defining the patient’s quality of life and
measuring the effects of COVID-19 on their health.
However, the two-limit Tobit regression analysis results
confirmed only the patient’s hospitalization status as an
effective factor on patient’s HRQoL. Depending on the
patient’s hospitalization status, a statistically significant






Mean (SE) Median (IQR)
Total 287 (100) 0.863 (0.01) 0.909 (0.21)
Having underlying disease
Yes 107 (37.28) 0.818 (0.02) 0.886 (0.26) < 0.01
No 180 (62.72) 0.889 (0.01) 0.923 (0.08)
Patient’s condition
Quarantine at home 123 (42.86) 0.896 (0.02) 0.98 (0.13) 0.01
General wards hospitalized 147 (51.22) 0.847 (0.01) 0.886 (0.24)
ICU hospitalized-non-intubated 13 (4.53) 0.766 (0.06) 0.808 (0.21)
ICU hospitalized-intubated 4 (1.39) 0.629 (0.13) 0.727 (0.33)
Hospitalized days
1 day 77 (26.83) 0.872 (0.02) 0.915 (0.19) 0.33
1–4 days 115 (40.07) 0.875 (0.02) 0.931 (0.17)
Over 4 days 95 (33.10) 0.840 (0.02) 0.896 (0.25)
Blood oxygen saturation
Normal (over 95%) 70 (24.39) 0.881 (0.01) 0.904 (0.19) 0.33
Below normal (under 95%) 217 (75.61) 0.857 (0.01) 0.923 (0.21)
Degree of lung involvement
Non/minor involved 64 (22.30) 0.927 (0.01) 0.966 (0.11) < 0.01
Poorly involved 190 (66.20) 0.844 (0.01) 0.894 (0.24)
Moderately involved 28 (9.76) 0.859 (0.04) 0.969 (0.20)
Severely involved 5 (1.74) 0.651 (0.11) 0.684 (0.24)
Perceived total health status (VASa)
> 0.7 206 (71.78) 0.869 (0.01) 0.917 (0.17) 0.19
0.5–0.7 23 (8.01) 0.894 (0.03) 0.969 (0.23)
< 0.5 58 (20.21) 0.826 (0.02) 0.864 (0.26)
aVisual Analogue Scale
Table 3 Estimation results of the multivariate two-limit Tobit model of utility value for COVID-19 disease
Variables Coefficient t statistics P-value 95% CI
Age −0.004 −4.71 < 0.01 [−0.005 – −0.002]
Place of residence 0.059 1.46 0.14 [−0.020–0.138]
Household dimension 0.013 1.36 0.17 [−0.006–0.032]
Having underlying disease 0.016 0.48 0.63 [−0.050–0.083]
Patient’s condition 0.107 4.02 < 0.01 [0.054–0.159]
Degree of lung involvement 0.036 1.27 0.20 [−0.020–0.092]
_Cons 0.485 3.23 < 0.01 [0.190–0.781]
Model statistics; Likelihood ratio = 47.33, P-value = < 0.01, Pseudo R2 = 0.302
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difference was seen in the average hospitalization days.
This amount was 12.75, 9.31, and 3.19 days for patients
admitted to the ICU with intubation and without intub-
ation, and for those hospitalized in the general ward of
the hospital, respectively. This result seems logical, be-
cause the more severe the disease of COVID-19, the
more the patient’s health decreases, and of course the
quality of life, in general, and the HRQoL, in particular,
reduces.
The findings showed that the severe symptoms of
COVID-19 were significantly higher among the elderly
than other age groups. As the incidence of underlying
disease was 76.19 and 26.34%, the rate of moderate to
high pulmonary involvement was 15.88 and 10.27%, and
the rate of SpO2 less than normal value was 88.89 and
71.88% among the elderly and other age groups respect-
ively. These observations explained the statistically
significant negative association between age and utility
values. As age increases, COVID-19 utility value
decreases dramatically. This value was 0.917 and 0.714
for the youth and elderly, respectively. This means that
COVID-19 damages 8.3 and 28.6% of HRQoL for these
two age groups, respectively. Other studies have also
confirmed higher morbidity and mortality among elderly
patients compared with others [25, 26]. This explanation
is also correct for the variable of having underlying
diseases. Respondents with underlying diseases showed
statistically significant and higher severe symptoms,
greater hospitalization rates in the ICU, and severe lung
involvement than their counterparts without underlying
diseases. Therefore, both age and underlying disease
factors can be introduced as confounding variables in
our analysis.
These results reflect those of Zhang et al. and Chen
et al. who also found that COVID-19 pandemic was
associated with mild but significant physical and psycho-
logical impairment of Chinese population. Also Chen
et al. showed that age and length of stay were strongly
associated with the patient’s HRQoL which is in agree-
ment with our findings [20, 27].
In terms of having a detrimental effect on HRQoL of
survivors, COVID-19 is comparable with Crohn’s
disease, ulcerative colitis [28], thalassemia patients who
receive oral iron chelator [29], rheumatoid arthritis [30],
and chronic Eustachian Tube dysfunction [31]. Of
course, epidemiological indicators, symptoms and effects
of these diseases on patients are not comparable. Rather,
the patient’s HRQoL is affected similarly from the pa-
tient’s perspective. This means that the common point
of these diseases is that they destroy a total of 15–17%
of patients’ HRQoL. In order to make a logical compari-
son between these diseases, we must calculate their
disease burden, which simultaneously measures and
presents both longevity and quality of life lost. In this
regard, COVID-19 seems to impose much more burden
on society than other diseases, because it has a much
higher incidence and mortality rate.
As far as we know, this study, for the first time, calcu-
lated and presented the utility value of COVID-19
disease which has various fundamental applications in
the burden of disease and economic evaluation studies.
To calculate the disease burden, we must separately cal-
culate the indexes of years of life lost due to premature
mortality (YLL) and years lived with disability (YLD)
[32]. Utility value for the YLL will be zero, but for YLD,
we can apply the obtained overall mean (median) value
for different health states in this study.
In addition, in cost-effectiveness studies on COVID-19,
researchers need to know the health states and associated
health utility values. Based on the findings of the univari-
ate and multivariate analysis models, it is recommended
that the patient’s hospitalization status (non-hospitalized,
general wards hospitalized, ICU hospitalized, and intu-
bated) be used as a reliable proxy to express the severity
and grading of COVID-19. Because the symptoms of the
disease and its complications have significant variations in
different patients, the same criteria cannot be considered
for all [33, 34]. Nevertheless, the patient’s hospitalization
status can represent all effects of COVID-19. The post-
hoc analysis confirmed that the mean (median) of utility
values obtained for each of the four conditions had a sta-
tistically significant difference compared with its higher-
grade at 0.01 significance level.
Multi-centeredness and having a sufficient sample size
in different health states were strengths of the current
study. However, the findings of the study should be
interpreted in light of its limitations. First, we invited the
most literate individuals of the family for the interview
as a proxy, instead of subjects below 15 years old, which
constituted 6.2% (18 individuals) of total participants.
This sample selection strategy could lead to over-
estimation of the disease utility value because the mean
(median) value of the disease utility was 0.966 (0.993)
and 0.856 (0.904) for patients younger and older than
15 years, respectively. Second, due to the impossibility of
face-to-face interviews with the participants because of
the prevention of possible transmission of the disease to
the interviewer, the telephone interview may have af-
fected the responses of the participants. Third, while the
respondents were newly recovered from the disease, the
study’s clinical findings can only be generalized to the
survivors. The severity of the disease among recovered
participants could be significantly lower than the whole
patients.
Conclusion
Hospitalization status of the patients with COVID-19 is
a valid factor in classification of or grading the disease.
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These patients lost approximately an average of 13% of
their HRQoL and the burden of disease caused by
COVID-19 appears to be substantial. Patients with
underlying disease, hospitalized in the ICU, or those
with severe lung involvement have the lowest utility
value compared to other patients with the disease, losing
about 18–33% of their HRQoL.. Moreover, findings of
the regression analysis indicated that the participants’
age and hospitalization status were the key determinants
of COVID-19 health utility value.
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